Denmark · Delayed Price · Currency is DKK Coloplast Statistics
Total Valuation
Coloplast has a market cap or net worth of DKK 140.46 billion. The enterprise value is 163.95 billion.
| Market Cap | 140.46B |
| Enterprise Value | 163.95B |
Important Dates
The last earnings date was Tuesday, August 19, 2025.
| Earnings Date | Aug 19, 2025 |
| Ex-Dividend Date | May 8, 2025 |
Share Statistics
Coloplast has 225.17 million shares outstanding. The number of shares has increased by 0.25% in one year.
| Current Share Class | 207.17M |
| Shares Outstanding | 225.17M |
| Shares Change (YoY) | +0.25% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 5.66% |
| Owned by Institutions (%) | 21.95% |
| Float | 142.64M |
Valuation Ratios
The trailing PE ratio is 34.51 and the forward PE ratio is 25.09. Coloplast's PEG ratio is 2.63.
| PE Ratio | 34.51 |
| Forward PE | 25.09 |
| PS Ratio | 5.04 |
| PB Ratio | 8.54 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 27.55 |
| P/OCF Ratio | 21.85 |
| PEG Ratio | 2.63 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.62, with an EV/FCF ratio of 32.16.
| EV / Earnings | 40.23 |
| EV / Sales | 5.88 |
| EV / EBITDA | 18.62 |
| EV / EBIT | 21.64 |
| EV / FCF | 32.16 |
Financial Position
The company has a current ratio of 1.00, with a Debt / Equity ratio of 1.47.
| Current Ratio | 1.00 |
| Quick Ratio | 0.61 |
| Debt / Equity | 1.47 |
| Debt / EBITDA | 2.75 |
| Debt / FCF | 4.75 |
| Interest Coverage | 9.54 |
Financial Efficiency
Return on equity (ROE) is 24.72% and return on invested capital (ROIC) is 11.59%.
| Return on Equity (ROE) | 24.72% |
| Return on Assets (ROA) | 9.82% |
| Return on Invested Capital (ROIC) | 11.59% |
| Return on Capital Employed (ROCE) | 20.30% |
| Revenue Per Employee | 1.66M |
| Profits Per Employee | 242,358 |
| Employee Count | 16,639 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.43 |
Taxes
In the past 12 months, Coloplast has paid 2.13 billion in taxes.
| Income Tax | 2.13B |
| Effective Tax Rate | 34.33% |
Stock Price Statistics
The stock price has decreased by -31.91% in the last 52 weeks. The beta is 0.55, so Coloplast's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -31.91% |
| 50-Day Moving Average | 607.53 |
| 200-Day Moving Average | 718.23 |
| Relative Strength Index (RSI) | 59.02 |
| Average Volume (20 Days) | 194,839 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Coloplast had revenue of DKK 27.87 billion and earned 4.08 billion in profits. Earnings per share was 18.07.
| Revenue | 27.87B |
| Gross Profit | 18.82B |
| Operating Income | 7.58B |
| Pretax Income | 6.21B |
| Net Income | 4.08B |
| EBITDA | 8.52B |
| EBIT | 7.58B |
| Earnings Per Share (EPS) | 18.07 |
Balance Sheet
The company has 726.00 million in cash and 24.22 billion in debt, giving a net cash position of -23.49 billion or -104.32 per share.
| Cash & Cash Equivalents | 726.00M |
| Total Debt | 24.22B |
| Net Cash | -23.49B |
| Net Cash Per Share | -104.32 |
| Equity (Book Value) | 16.45B |
| Book Value Per Share | 73.05 |
| Working Capital | 3.00M |
Cash Flow
In the last 12 months, operating cash flow was 6.43 billion and capital expenditures -1.33 billion, giving a free cash flow of 5.10 billion.
| Operating Cash Flow | 6.43B |
| Capital Expenditures | -1.33B |
| Free Cash Flow | 5.10B |
| FCF Per Share | 22.64 |
Margins
Gross margin is 67.55%, with operating and profit margins of 27.19% and 14.62%.
| Gross Margin | 67.55% |
| Operating Margin | 27.19% |
| Pretax Margin | 22.27% |
| Profit Margin | 14.62% |
| EBITDA Margin | 30.57% |
| EBIT Margin | 27.19% |
| FCF Margin | 18.29% |
Dividends & Yields
This stock pays an annual dividend of 22.00, which amounts to a dividend yield of 3.53%.
| Dividend Per Share | 22.00 |
| Dividend Yield | 3.53% |
| Dividend Growth (YoY) | 4.76% |
| Years of Dividend Growth | 16 |
| Payout Ratio | 121.67% |
| Buyback Yield | -0.25% |
| Shareholder Yield | 3.34% |
| Earnings Yield | 2.90% |
| FCF Yield | 3.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 19, 2012. It was a forward split with a ratio of 5.
| Last Split Date | Dec 19, 2012 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Coloplast has an Altman Z-Score of 5.05 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.05 |
| Piotroski F-Score | 6 |